Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Total Liabilities (2020 - 2025)

Biofrontera has reported Total Liabilities over the past 6 years, most recently at $18.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $18.1 million for Q4 2025, up 2.35% from a year ago — trailing twelve months through Dec 2025 was $18.1 million (up 2.35% YoY), and the annual figure for FY2025 was $18.1 million, up 2.35%.
  • Total Liabilities for Q4 2025 was $18.1 million at Biofrontera, roughly flat from $18.0 million in the prior quarter.
  • Over the last five years, Total Liabilities for BFRIW hit a ceiling of $41.9 million in Q4 2021 and a floor of -$7.2 million in Q2 2023.
  • Median Total Liabilities over the past 5 years was $24.0 million (2023), compared with a mean of $21.0 million.
  • Biggest five-year swings in Total Liabilities: soared 2560.31% in 2022 and later plummeted 119.71% in 2023.
  • Biofrontera's Total Liabilities stood at $41.9 million in 2021, then plummeted by 35.52% to $27.0 million in 2022, then fell by 14.32% to $23.1 million in 2023, then dropped by 23.64% to $17.7 million in 2024, then grew by 2.35% to $18.1 million in 2025.
  • The last three reported values for Total Liabilities were $18.1 million (Q4 2025), $18.0 million (Q3 2025), and $24.8 million (Q2 2025) per Business Quant data.